Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Post-traumatic stress disorder is a mental health condition that gets activated by a traumatic event either experiencing or witnessing such as natural disaster, serious accident, sexual violence, a terrorist act, etc. PTSD can occur in people at all ages. Some of the major symptoms of post-traumatic stress disorder are intrusive memories, avoidance, negative changes in thinking and mood, as well as changes in emotional and physical reactions. The common drugs prescribed by the doctors are antidepressants, anti-anxiety medications, fluoxetine, and others.
Post-traumatic Stress Disorder treatment market – Impact of Coronavirus (COVID-19) Pandemic
During the pandemic, the demand for the treatment of post-trauma stress disorder has increased. According to PTSD Foundation of America, as of now, the COVID-19 infection and post-traumatic stress disorder do not have direct connection but, the norms to stop the spread of virus from person to person could be a potential trigger for post-trauma stress disorder. The norms made by the WHO to stop the spread of COVID infection included maintaining social distance and quarantining patients if they were found COVID-19 positive. These may have led to a gradual increase in the number of patients for post-trauma stress disorder. According to an article published by Psychiatric Times, there is 16.8% of incidence of PTSD symptoms in nurses of China.
The global post-traumatic stress disorder treatment market is estimated to be valued at US$ 990.7 million in 2021 and is expected to exhibit a CAGR of 4.2% during the forecast period (2021-2028).
Fig.1 : Global Post-traumatic Stress Disorder treatment Market Share (%), Application Analysis, 2021 and 2028
Rising number of clinical trials is expected to boost growth of the post-traumatic stress disorder treatment market
Rising number of clinical trials for new drug development for the treatment of post-traumatic stress disorder treatment is expected to drive the market growth over the forecast period. For instance, Otsuka Pharmaceutical Development & Commercialization, Inc. initiated clinical trial for Brexpiprazole as combination therapy with Sertraline in treatment of adults with PTSD. The trial is in phase 3. The study was initiated in October 2019 and is expected to conclude in June 2022. Brexpiprazole is an atypical antipsychotic used in the treatment of schizophrenia and other major depressive disorders.
Post-traumatic Stress Disorder treatment Market Report Coverage
||Market Size in 2021:
||US$ 990.7 Mn
|Historical Data for:
||2017 to 2020
||2022 to 2028
|Forecast Period 2021 to 2028 CAGR:
||2028 Value Projection:
||US$ 1,380.0 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of APAC
- Middle East: GCC, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Drug Type: Antidepressants, Monoamine Oxidase (MAOs), Antipsychotics or Second Generation Antipsychotics (SGOs), Beta- Blockers, Benzodiazepines, Others
- By Application: Adult, Children.
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Allergan PLC, AstraZeneca, Eily Lilly and Company, GlaxoSmithKline PLC, Sun Pharmaceuticals Pvt Ltd, Bristol-Myers Squibb, Johnson and Johnson, Pfizer Inc, Aurobindo Pharma, Amneal Pharmaceuticals LLC, Apotex Inc., Teva Pharmaceuticals Industries Ltd, Mylan Pharmaceuticals, and Bausch Health Companies Inc.
- Increasing clinical trials
- Increasing research and development
|Restraints & Challenges:
- Adverse side effects and lack of awareness
Post-traumatic Stress Disorder treatment market – Restraints
There are only two drugs which have been approved by the USFDA (i.e. Sertraline and Paroxetine) for the treatment of post-traumatic stress disorder, however, they show adverse side effects. As these medications show adverse side effects, the regulatory bodies do not approve the medications without proper clinical trials. These side effects are expected to hamper the growth of PTSD treatment market. For instance, the primary side effects of sertraline include syncope, lightheadedness, diarrhea, nausea, sweating, dizziness, xerostomia, confusion, hallucinations, tremor, somnolence, impotency, fatigue, rhinitis, and female sexual disorder. Also, there is a bleeding risk associated with sertraline, as it may inhibit platelet aggregation. The side effects associated with Paroxetine include changes in mood, anxiety or behavior, serotonin syndrome or neuroleptic malignant syndrome-like reactions, eye problems, severe allergic reactions, bruising/ bleeding, seizures or convulsions, manic episodes, changes in appetite or weight, low sodium levels, and bone fracture.
Post-Traumatic Stress Disorder treatment market – Regional Analysis
On the basis of region, the global post-traumatic stress disorder treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
The increasing number of clinical trials is one of the major factors propelling growth of the North America post-traumatic stress disorder treatment market. For instance, in December 2020, Tonix Pharmaceuticals Holding Corp. announced topline results from its Phase 3 RECOVERY study1 of TNX-102 SL 5.6 mg, for the treatment of civilian and military-related posttraumatic stress disorder (PTSD). TNX-102 SL is generally well tolerated and no new safety signals were observed.
Moreover, the Europe post-traumatic stress disorder treatment market is expected to witness significant growth during the forecast period owing to increasing distribution agreements. For instance, in May 2020, Allied Corp. announced the signing of manufacturing and distribution agreement with MGC Pharmaceuticals. According to the agreement, MGC Pharmaceuticals will manufacture Allied Corp.’s products. MGC currently has cannabis-based pharmaceutical products for sale in Europe and has demonstrated a proven ability to commercialize these products. Commercialization of Allied’s post-traumatic stress disorder (PTSD) treatment products into the European, South American, and North American marketplace is a key plan of Allied’s strategies.
Fig. 2: Global Post-traumatic Stress Disorder Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2028
Global Post-traumatic Stress Disorder Treatment Market - Competitive Landscape
Key players operating in the global post-traumatic stress disorder treatment market include Allergan PLC, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, Sun Pharmaceuticals Pvt Ltd, Bristol-Myers Squibb, Johnson and Johnson, Pfizer Inc, Aurobindu Inc., Amneal Pharmaceuticals LLC, Apotex Inc., Teva Pharmaceuticals Industries Ltd, Mylan Pharmaceuticals, and Bausch Health Companies Inc.